Blog · Evidence, in plain language

A depression headset was approved for home use. Here is what that means.

Patients in medication visits are asking about a headset they can use at home for depression, and for the first time there is a version of that idea with a full FDA approval behind it. The approval is real. So is the disagreement about it, including a caution written into the FDA document itself. This post lays out both, because a medication visit is exactly where a claim like this should be weighed carefully.

By Karel Winner, DNP, PMHNP-BC · Published November 17, 2026

This post is education, not medical advice. It explains a regulator decision, one clinical trial, and a published critique. It is not a recommendation to use, buy, or stop any treatment, and it gives no dosing information for any medicine.

What was actually approved

On December 8, 2025, the U.S. Food and Drug Administration gave premarket approval, application P230024, to a device called Flow FL-100, made by Flow Neuroscience AB. Premarket approval is the FDA most demanding device pathway. A short editorial in the journal Brain Stimulation describes the decision as the first FDA premarket approval for a home-use non-invasive brain stimulation device specifically indicated for depression treatment. The approved wording is narrow, and the narrowness matters. The device is intended for the treatment of moderate to severe major depressive disorder in the current episode, either as monotherapy or as an adjunctive treatment, in patients 18 years and older who are not considered treatment refractory to medication. In plain terms: adults, a current moderate to severe depressive episode, used alone or added to other treatment, and not for people whose depression is considered resistant to medication.

How the device works, in plain language

The technique is called transcranial direct current stimulation, shortened to tDCS. The FDA summary describes it as a low-intensity direct electrical current delivered to specific areas of the brain through electrodes placed on the scalp, which may change how readily brain cells become active. The FL-100 system combines a Bluetooth headset, single-use saline pads, a smartphone app that guides sessions and tracks use, and a clinician platform through which a clinician can monitor use and set stimulation parameters. In the study behind the approval, sessions lasted 30 minutes, held five times a week for the first three weeks and then up to three times a week, for 36 sessions over 10 weeks. That schedule is a description of how the trial was run. It is not an instruction in this post, and home use in the trial was supervised remotely, with staff directly supervising the first use.

What the one pivotal trial found

The approval rests mainly on one study, called Empower, published in Nature Medicine. It was a fully remote, multisite, double-blind, randomized trial: 174 adults with a current depressive episode of at least moderate severity were assigned to active stimulation (87 people) or to a sham device that mimicked the start of stimulation and then delivered none (87 people). After 10 weeks, scores on the Hamilton Depression Rating Scale had improved by 9.41 points in the active group and 7.14 points in the sham group, an extra improvement of about 2.3 points for active treatment, which was statistically significant (P = 0.012). On that same scale, 54.4 percent of the active group met the study definition of response, compared with 26.9 percent on sham, and 44.9 percent met the definition of remission, compared with 21.8 percent on sham. A second scale, the MADRS, pointed the same way. Two things deserve equal weight here. The differences were real by the usual statistical tests. And the sham group also improved a great deal, which is common in depression trials and is one reason a comparison group matters more than any single percentage quoted alone.

Why the FDA itself flagged uncertainty

The FDA summary contains an unusual, plainly worded limit, and patients deserve to hear it in the regulator own terms. The agency wrote that, in its evaluation based on the Empower study, there is a moderate level of uncertainty of benefit, for three named reasons: unblinding, the lack of a prespecified clinically significant change in Hamilton scores, and conflicting results from the wider literature. Unblinding is not a technical footnote. At week 10, 77.6 percent of people in the active group correctly guessed they were receiving active treatment, while only 40.7 percent of the sham group correctly guessed they were on sham, a statistically significant difference. The FDA re-ran the numbers with the guesses balanced, and the estimated advantage shrank from 2.3 points to about 2.0 to 2.12 points, still in favor of active treatment, but smaller. In 2026, a commentary in The Lancet Psychiatry went further, arguing in its title that the approval is not yet scientifically justified, that the efficacy evidence is not convincing, and that risks from misuse and unsupervised use in moderate to severe depression have not been addressed. Supporters and critics are reading the same trial. The honest summary is that one well-run remote trial found a modest benefit, the regulator approved the device while naming its doubts, and independent specialists remain divided.

Safety, as the FDA lists it

The adverse effects observed in the study, as listed by the FDA, were mostly at the skin or during stimulation: dry skin, skin irritation or redness where the electrodes sat, stinging, tingling, numbness or a burning feeling during stimulation, and skin burn. The list also includes headache, tinnitus, sleepiness, trouble concentrating during stimulation, and acute mood change or worsening depression. The device is not to be used where there are open wounds, broken skin, or damaged skin at the electrode site, or where there is metallic skull reconstruction at that site. Worsening depression on any new treatment, device or medicine, is a reason to contact the treating clinician promptly rather than to push through a schedule, and the crisis options below apply at any point.

Where this fits in a medication plan

This approval does not move the established options, and it does not answer the question patients most often bring with it, which is whether they can stop a medicine that is helping, or avoid starting one. The trial studied the device alone and added to existing treatment, in people who were not considered resistant to medication. It did not compare the device with an antidepressant, with therapy, or with clinic-based brain stimulation, so the evidence cannot rank it against any of them. It also says nothing about bipolar depression, depression in teenagers, or depression that has already resisted medication, because those groups are outside the approved wording. For a patient whose depression is not responding, that last point cuts the other way from the marketing: the approved group specifically excludes treatment refractory illness. The useful visit question is the older one: what, exactly, is not working in the current plan, and which option with evidence for your situation addresses that problem. This device may belong in that conversation for some adults. It should enter it with its uncertainty attached, not stripped off.

Sources

This post is based on the regulator and journal sources below. Every number in it comes from the FDA summary or the published trial record.

U.S. Food and Drug Administration, Summary of Safety and Effectiveness Data, Premarket Approval P230024, Flow FL-100, notice of approval December 8, 2025: the approved indication, the device description, the Empower study results, the blinding analysis, the adverse effects, and the FDA statement of moderate uncertainty of benefit. FDA Summary of Safety and Effectiveness Data.

Woodham and colleagues, Nature Medicine (2025), volume 31, pages 87 to 95: a fully remote, multisite, double-blind, placebo-controlled randomized trial of 10-week home-based transcranial direct current stimulation in major depressive disorder, 174 participants, ClinicalTrials.gov NCT05202119. PubMed record.

Bikson, Brunoni, and George, Brain Stimulation (2026), volume 19, article 103021: the approval is the first FDA premarket approval for a home-use non-invasive brain stimulation device specifically indicated for depression treatment. PubMed record.

Commentary in The Lancet Psychiatry (2026): US FDA premarket approval of tDCS depression treatment is not yet scientifically justified. The authors argue the efficacy evidence is not convincing and that risks from misuse and unsupervised use have not been addressed. The Lancet Psychiatry.

Please read this part

Nothing here is medical advice, and reading it does not create a treatment relationship. A device approval describes a studied group and a studied way of using the device. It cannot predict what the device, or any other treatment, will do for you. If your current treatment is working, a headline is not a reason to change it. If it is not working, bring that problem, and this option if you wish, to a medication visit where your diagnosis, your history, and your other treatments can be weighed together.

If you are having thoughts of harming yourself, help is available now: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service. If someone is in immediate danger, call 911. The crisis page lists more options.

“A medication that has done its job deserves a careful goodbye, planned like the treatment it was.”

Plan the goodbye: deprescribing, as a service